New Imaging Approach Promises Insights Into Multiple Sclerosis Newswise Tue, 17 Apr 2007 2:21 PM PDT Researchers have developed a way to use three types of microscopic imaging techniques simultaneously to analyze living tissue and learn more about the molecular mechanisms of multiple sclerosis, information that could help lead to earlier detection and new treatments.

Natalizumab helps reduce vision loss News-Medical-Net Wed, 18 Apr 2007 2:19 AM PDT A drug that slows disability and reduces relapse rates in multiple sclerosis (MS) has been found to also reduce vision loss in patients with relapsing MS. Vision loss is one of the most common and debilitating symptoms of MS.

MS patients not receiving medications to slow disease progression News-Medical-Net Wed, 18 Apr 2007 2:19 AM PDT Neurologists at Wake Forest University Baptist Medical Center have found that many patients diagnosed with multiple sclerosis (MS) are not taking or being prescribed drugs approved to treat the disease.

New One-Year Pharmacoeconomic Study Shows Avonex? Is Cost-Effective Relative To Other Interferon Therapies For Multiple ... Medical News Today Wed, 18 Apr 2007 0:07 AM PDT Biogen Idec Inc. (NASDAQ: BIIB) announced today that one-year data presented at the Academy of Managed Care Pharmacy's (AMCP) 2007 Annual Meeting show that AVONEX? (Interferon beta-1a) is a cost-effective therapy in multiple sclerosis (MS) when compared to other interferon beta treatments. [click link for full article]

Natalizumab (Tysabri) reduces vision loss in MS patients News-Medical-Net Wed, 18 Apr 2007 3:49 AM PDT According to a study that appears in the April 17 issue of Neurology, researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI), a drug that slows disability and reduces relapse rates in patients with multiple sclerosis (MS), also reduces vision loss in patients with relapsing MS.

Teva Reveals Encouraging Copaxone Data RedNova Tue, 17 Apr 2007 3:02 PM PDT Teva Pharmaceuticals has revealed that higher doses of its multiple sclerosis drug Copaxone could be more effective in reducing inflammation, according to results of a phase II study. The study compared a 40mg dose of Copaxone given daily to the currently approved Copaxone 20mg dose.

No hurdles big enough: Inspiration through wife's disease and weight loss guide his marathon effort Eagle-Tribune Online Wed, 18 Apr 2007 6:57 AM PDT BOSTON - Chris Larcome had no problem searching for inspiration through the pain, the wind, rain, mud, cramping and every other roadblock thrown his way for 26.2 miles from Hopkinton to Boston yesterday.

Effective noninvasive treatment option for trigeminal neuralgia-related pain
News-Medical-Net Wed, 18 Apr 2007 2:49 AM PDT
Trigeminal neuralgia or tic douloureux is sometimes described as the most excruciating pain known to humanity.